Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$2.93 ▼ -0.02
(-0.68%)
MKT CAP: $450.0M • VOL: 3.23M
52W L $2 52W H $4
ROARABLE / RQD
D- • 37/100
PIOTROSKI
3 / 9
EDIT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $40.5M | $32.3M | $78.1M |
| YoY Revenue Growth % | +25.4% | -58.6% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$160.0M | -$251.2M | -$169.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$160.1M | -$237.1M | -$153.2M |
| EBITDA (Normalized) | -$159.5M | -$244.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$165.2M | -$210.3M | -$132.2M |
| Capital Expenditures (CapEx) | $607.0K | $8.8M | — |
| Free Cash Flow (FCF) | -$165.8M | -$219.1M | -$132.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $146.6M | $131.5M | — |
| Total Debt (Short + Long Term) | $53.6M | $52.4M | — |
| Total Stockholders' Equity | $27.3M | $134.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EDIT.